Lipid peroxidation in patients with schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 64, Issue 5, 2010, Pages 469-475

  Dietrich Muszalska, Anna ^a   Kontek, Bogdan ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

lipid peroxidation; olanzapine; risperidone; schizophrenia; total antioxidative capacity

Indexed keywords

2,2' AZINOBIS(3 ETHYLBENZOTHIAZOLINE 6 SULFONIC ACID); OLANZAPINE; RISPERIDONE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DECOLORIZATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMAN; IN VITRO STUDY; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BENZOTHIAZOLES; BIOLOGICAL MARKERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; RISPERIDONE; SCHIZOPHRENIA; SULFONIC ACIDS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; YOUNG ADULT;

EID: 77957331098     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2010.02132.x     Document Type: Article

References (47)

1. Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities and the diagnosis and treatment of schizophrenia. Biol. Psychiatry 2000 47 : 8 21. (Pubitemid 30016075)
2. Ross BM. Phospholipid and eicosanoid signaling disturbances in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2003 69 : 407 412.
3. Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involvement in schizophrenia pathophysiology. Encephale 2006 32 : 244 252. (Pubitemid 43670234)
4. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001 15 : 287 310. (Pubitemid 32337052)
5. Du Bois TM, Deng C, Huang XF. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005 29 : 878 888. (Pubitemid 41080107)
6. Dietrich-Muszalska A, Olas B. Isoprostanes as indicators of oxidative stress in schizophrenia. World J. Biol. Psychiatry 2009 10 : 27 33.
7. Horrobin DE, Glen AIM, Vaddadi K. The membrane hypothesis of schizophrenia. Schizophr. Res. 1994 13 : 195 202. (Pubitemid 24302649)
8. Gama CS, Salvador M, Andreazza AC et al. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci. Lett. 2008 433 : 270 273.
9. Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh VV, Mahadik SP. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002 58 : 1 10. (Pubitemid 35287278)
10. Arvindakshan M, Sitasawad S, Debsikdar V et al. Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol. Psychiatry 2003 53 : 56 64. (Pubitemid 36050936)
11. Mahadik SP, Mukherjee S, Scheffer R, Correnti EE, Mahadik JS. Elevated plasma lipid peroxidases at the onset of nonaffective psychosis. Biol. Psychiatry 1998 43 : 674 679. (Pubitemid 28222388)
12. Peet M, Zhi JZ, Selvam K, Ramchand CN. Plasma TBARS levels in unmedicated chronic schizophrenic patients. Schizophr. Res. 1997 24 : 66.
13. Akyol O, Herken H, Zu E et al. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002 26 : 995 1005. (Pubitemid 35245568)
14. Reddy R, Kelkar H, Mahadik SP et al. Free radicals and neurological signs in chronic schizophrenic patients. Biol. Psychiatry 1994 35 : 699 700.
15. Gama CS, Salvador M, Andreazza AC, Kapczinski F, Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006 30 : 512 515.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association
17. Sheehan DV, Lecrubier Y, Sheenhan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998 59 : 22 33. (Pubitemid 29001829)
18. Rice-Evans CA, Diplock AT, Symons MCR. Techniques in Free Radical Research. Elsevier
19. Re R, Pellegrini N, Proteggente A, Pannala A, Yang M, Rice-Evans C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. Free Radic. Biol. Med. 1999 26 : 1231 1237. (Pubitemid 29262709)
20. Bartosz G. Total antioxidant capacity. Adv. Clin. Chem. 2003 37 : 219 292. (Pubitemid 137639199)
21. Kay SR, Fisz-Bein A, Opler LA. The positive and negative syndrome scale (PANNS) for schizophrenia. Schizophr. Bull. 1987 13 : 261 274.
22. Yao JK, van Kammen DP, Gurkis WJ. Correlation of fatty acid abnormalities with clinical measures in schizophrenia. Schizophr. Res. 1994 11 : 124.
23. Reddy RD, Yao JK. Environmental factors and membrane polyunsaturated fatty acids in schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2003 69 : 385 391. (Pubitemid 37464047)
24. Bartosz G. Free radicals and the developmental pathology of schizophrenic burnout commentary Integr. Psychiatry 1987 5 : 43 44.
25. Van Kammen D, Yao JG, Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann. N. Y. Acad. Sci. 1989 559 : 411 423. (Pubitemid 19215855)
26. Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr. Clin. North Am. 2003 26 : 85 102.
27. Yao JK, Reddy R, McElhinnyl G, van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr. Res. 1998 32 : 1 8. (Pubitemid 28338118)
28. Mukherjee S, Mahadik SP, Correnti EE et al. The antioxidant defenses system at the onset of psychosis. Biol. Psychiatry 1994 35 : 701.
29. Dietrich-Muszalska A, Olas B, Rabe-Jabłońska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005 16 : 386. (Pubitemid 41564335)
30. Khan NS, Das I. Oxidative stress and superoxide dismutase in schizophrenia. Biochem. Soc. Trans. 1997 25 : 418S. (Pubitemid 27417040)
31. Jeding I, Evans PJ, Akanmu D et al. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem. Pharmacol. 1995 49 : 359 365.
32. Mahadik SP, Mukherjee S, Correnti EE, Scheffer R. Elevated levels of lipid peroxidation products in plasma of drug-naive patients at the onset of psychosis. Schizophr. Res. 1995 15 : 66.
33. Zhang XY, Tan YL, Cao LY et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006 81 : 291 300.
34. Dietrich-Muszalska A. The impact of haloperidol on lipids peroxidation in human blood platelets and plasma at in vitro studies. Psychiatria i Psychologia Kliniczna 2004 3 : 150 156.
35. Dietrich-Muszalska A. Evaluation of the effects of different concentrations of risperidone, corresponding to the drug doses used in treatment of schizophrenic patients, on lipid peroxidation in plasma and blood platelets at in vitro studies. Psychiatria i Psychologia Kliniczna 2004 4 : 215 223.
36. Dietrich-Muszalska A. The impact of different concentrations of clozapine on changes of lipid peroxidation in human plasma - in vitro studies. Psychiatria i Psychologia Kliniczna 2005 5 : 18 25.
37. Dietrich-Muszalska A, Olas B. Inhibitory effects of polyphenol compounds on lipid peroxidation caused by antipsychotics (haloperidol and amisulpride) in human plasma in vitro. World J. Biol. Psychiatry 2010 11 : 276 281.
38. Xu H, Wang H, Zhuang L et al. Demonstration of an anti-oxidative stress mechanism of quetiapine. FEBS J. 2008 275 : 3718 3728.
39. Wang H, Xu H, Dyck LE, Li XM. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide (25-35)-induced oxidative stress and the ensuing apoptosis. J. Neurosci. Res. 2005 81 : 572 580. (Pubitemid 41297394)
40. Cadet JL, Lohr JB, Jeste DV. Free radicals and tardive dyskinesia. Trends Neurosci. 1986 9 : 107 108.
41. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 1998 71 : 1002 1012. (Pubitemid 28390254)
42. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005 10 : 79 104. (Pubitemid 40139590)
43. Möller HJ. Novel antipsychotics in the long-term treatment of schizophrenia. World J. Biol. Psychiatry 2004 5 : 9 19. (Pubitemid 44121723)
44. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J. Biol. Psychiatry 2005 6 : 132 191.
45. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term of schizophrenia. World J. Biol. Psychiatry 2006 7 : 5 40. (Pubitemid 43878525)
46. Kropp S, Kern V, Lange K et al. Oxidative stress during treatment with first- and second-generation antipsychotics. J. Neuropsychiatr. 2005 17 : 227 231. (Pubitemid 41350611)
47. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004 49 : 205 209. (Pubitemid 38594573)